The BioIndustry Association has expressed "disappointment" with the revised European Directive 86/609 on the use of animals in scientific procedures (Animal Testing Directive) adopted by the College of European Commissioners in Brussels.
Aisling Burnand, the BIA's chief executive said: "one would expect that the proposed Directive would take into account the most up to date scientific and ethical practices, however, this does not seem to be the case." She added that "the research community will feel that their core concerns have not been respected and indeed in some areas it could even have a negative impact on animal welfare."
The BIA has particular concerns over several aspects of the directive, including: "unnecessary regulatory burdens" imposed on scientists that "do nothing for - and in some cases worsen - animal welfare;" and short- and long-term effects of the proposed Directive on the ability of scientists in both industry and academia to undertake essential research that could lead to substantial benefits for human health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze